SR 47063

Drug Profile

SR 47063

Latest Information Update: 02 Jun 1995

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antiarrhythmics; Antihypertensives; Benzopyrans
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Hypertension; Myocardial ischaemia

Most Recent Events

  • 02 Jun 1995 Discontinued-I for Myocardial ischaemia in France (Unknown route)
  • 02 Jun 1995 Discontinued-Preclinical for Myocardial ischaemia in Belgium (Unknown route)
  • 02 Jun 1995 Discontinued-I for Hypertension in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top